Smart Tech-Based Nutrition and Exercise for Sarcopenia Risk.

NCT ID: NCT07230210

Last Updated: 2025-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-03

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sarcopenia, characterized by muscle loss and weakness, is a major health issue among older adults and impacts mobility and quality of life. This study addresses the current lack of long-term, technology-assisted support for managing this condition at home. This randomized controlled trial (RCT) will evaluate a 12-week smart-technology-based program for 60 older adults at risk of sarcopenia.

Intervention:

Participants in the intervention group will receive a technology-assisted program delivered through a Line Bot system. The platform provides personalized exercise training videos, nutrition education, daily reminders, and a point-based logging system to support adherence and monitor engagement. The control group will receive standard clinic-based care.

Purpose:

The study aims to examine whether the smart technology intervention can improve muscle mass, physical performance, quality of life, and self-management ability among older adults at risk of sarcopenia.

Expected Benefit:

The digital intervention is anticipated to offer a more effective, accessible, and sustainable approach compared with standard care, providing practical support for preventing muscle decline in community-dwelling older adults

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This randomized controlled trial (RCT) is designed as a 12-week intervention to evaluate the efficacy of a smart technology-assisted nutrition and exercise program for community-dwelling older adults (aged ≥ 65 years) at risk of sarcopenia. Participants (N = 60) will be randomly assigned to either the intervention group (n = 30) or the control group (n = 30). Data will be collected at baseline, week 8 (mid-intervention), and week 12 (post-intervention).

Intervention Group:

Participants will receive the 12-week program delivered through a dedicated Line Bot platform. Core components include:

Exercise Training: Three progressive exercise videos (resistance, aerobic, and balance training) designed to enhance muscle function.

Nutrition Education: One video focusing on adequate protein intake and dietary habits essential for muscle maintenance.

Smart Technology Features: The Line Bot functions as a personalized case management tool, offering daily reminders for exercise and protein intake, an interactive calculator for estimating daily protein consumption, and a digital logging system with motivational rewards to support adherence and self-management behaviors.

Control Group:

Participants will receive standard outpatient care and general health education pamphlets. They will not receive access to the Line Bot system, exercise videos, or personalized support.

Primary outcome data will be collected at week 12. Statistical analyses will include descriptive statistics and inferential methods, such as repeated measures analysis of variance (ANOVA), to examine the effectiveness of the intervention.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants are randomized into two parallel arms: the Intervention Group (n=30) and the Control Group (n=30). Both groups will remain in their assigned arm for the entire 12-week study duration.
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

This study is an open-label randomized controlled trial (RCT) due to the complexity of the Line Bot intervention and the involvement of the same study personnel in both intervention delivery and data collection.

Potential sources of bias are minimized through the following procedures:

Random Allocation: Group assignment is conducted using sealed, opaque envelopes to ensure unbiased randomization.

Objective Primary Outcomes: Primary outcomes such as muscle mass and physical function are assessed using standardized and quantifiable measurement instruments.

Standardized Training: All study personnel responsible for data collection follow standardized operating procedures to ensure consistency across both groups.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Smart Technology-Assisted Exercise and Nutrition Program

Participants in the intervention group (n=30) will receive a 12-week smart technology-assisted combined exercise and nutrition program. The intervention is delivered via a dedicated Line Bot platform, which provides: 1) Three progressive exercise training videos (resistance, aerobic, and balance) , \*\*with the goal of participants completing five exercise sessions per week using the provided materials\*\*. 2) Nutrition education videos focusing on protein intake. 3) Interactive features including daily reminders, protein intake calculation tools, and a digital diary with motivational elements to promote adherence and self-management.

Group Type EXPERIMENTAL

The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in

Intervention Type BEHAVIORAL

The 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated \*\*Line Bot platform\*\*. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week.

Standard Outpatient Care

Participants in the control group (n=30) will receive standard outpatient care for sarcopenia risk management, which includes general health education pamphlets and regular follow-ups at the clinic. They will not receive any specialized exercise training, nutrition videos, or access to the Line Bot platform during the 12-week intervention period.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The 12-week exercise component is delivered via the dedicated Line Bot platform. It includes three progressive exercise training videos (resistance, balance) . Participants are in

The 12-week progressive exercise program (resistance, aerobic, and balance training) is uniquely delivered and monitored via a dedicated \*\*Line Bot platform\*\*. This differentiates it from traditional in-person or non-interactive video programs. The platform includes interactive features like daily reminders and a digital diary to enhance adherence and support participant self-management, aiming for five exercise sessions per week.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Score ≥ 11 on the SARC-CalF questionnaire, indicating risk of sarcopenia.

No evident functional impairment in the limbs and able to complete handgrip strength, walking speed, and muscle mass assessments.

Possesses basic reading, writing, and calculation abilities sufficient to understand study-related materials and complete informed consent and daily logs.

Owns a smartphone and has used it for at least one year, with basic operational ability (e.g., sending and receiving LINE messages, scanning QR codes).

Exclusion Criteria

Self-reported functional impairment in any limb.

Requires assistance from a wheelchair, walker, or cane for ambulation.

Has an implanted cardiac pacemaker.

Currently participating in, or planning to participate in, other physical training courses or nutrition programs during the study period.
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HSIAO MEI LAN

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

HSIAO MEI LAN

Master's Student and Geriatric Case Manager

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

BuddhistTCGH

Hualien City, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mei Lan Hsiao, RN

Role: CONTACT

+886-978130926

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mei Lan Geriatric Case Manager

Role: primary

0978130926

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB114-215-B

Identifier Type: OTHER

Identifier Source: secondary_id

IRB114-215-B

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Muscle Biopsies in Healthy Volunteers
NCT01431677 TERMINATED NA